At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 367 enrolled
Drug / intervention
CC-93538drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis
In Brief
A Phase 3 clinical trial evaluating CC-93538 for Eosinophilic Esophagitis. Completed, enrolled 367 participants across 167 sites in 15 countries.
Detailed Summary
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEosinophilic Esophagitis
CountriesArgentina, Australia, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartAug 2022
Primary CompletionAug 2025
TodayJul 2026
First PostedAug 5, 2021
Enrollment StartAug 9, 2022
Primary CompletionAug 14, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.9 years ago
Interventions
CC-93538drug
CC-93538